Skip to main content
OpenTrials
Completed

NCT Number: NCT07653126

A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Novartis Investigative Site, Essen, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin [CUP], any Grade).
  • Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.

Exclusion criteria

  • Received a combination of PRRT with chemotherapy.
  • Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Treatment and study plan

Primary outcomes

  1. Baseline Demographics

    Time frame: Baseline

  2. Number of Patients by Tumor Status

    Time frame: Baseline

  3. Duration Between Initial Diagnosis and Initiation of Primary PRRT

    Time frame: Baseline

  4. Number of Patients by PRRT Line of Therapy

    Time frame: Approximately 1 year

  5. Number of Patients by Type of PRRT Received

    Time frame: Approximately 1 year

  6. PRRT Dosage

    Time frame: Approximately 1 year

  7. Number of Patients by Treatment Interval

    Time frame: Approximately 1 year

  8. Number of Patients by Co-medication

    Time frame: Approximately 1 year

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)

Acronym: LUNET-2

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jun 17, 2026
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.